RxDoctor Payments Data

Kourosh Saghafi

Geriatric Medicine · Parma, OHNPI 1659358950

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Johnson & Johnson at 39.2% of the total. Reporting peaked in 2019 at $206 and has fallen 86.8% since, to $27 in 2025.

$279in general payments, 2019–2025

Across 6 payments — averaging $46.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$109
  • Sanofi-aventis U.S. LLC$96
  • Medtronic$27
  • Abbott$24
  • Biohaven Pharmaceutical Holding Company Ltd.$13
  • GRT US Holding, Inc.$9

What the payments were for

  • Food & beverage$279100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$279 in reported general payments places this provider in the 60th percentile of 146 geriatric medicine providers in Ohio.

See all geriatric medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$203,425
Medicare patients
389
Services billed
2,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban331$87,940
TrulicityDulaglutide39$37,353
XareltoRivaroxaban109$33,347
JardianceEmpagliflozin17$13,871
EntrestoSacubitril/Valsartan30$11,094
Atorvastatin Calcium638$6,204
Divalproex Sodium222$6,062
MyrbetriqMirabegron27$4,952
Midodrine Hcl85$4,709
FarxigaDapagliflozin Propanediol13$4,569
ArexvyRsvpref3 Antigen/As01e/Pf15$4,452
Gabapentin237$3,882
Potassium Chloride209$3,844
BrilintaTicagrelor14$3,571
Metoprolol Succinate302$3,478

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$109$33,347109 claims
Sanofi-aventis U.S. LLCLantus$96$1,55321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 146 geriatric medicine providers in Ohio.

Other geriatric medicine in Parma

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →